Document Detail


Antihypertensive efficacy of candesartan in comparison to losartan: the CLAIM study.
MedLine Citation:
PMID:  11416677     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An 8-week, multicenter, double-blind, randomized, parallel-group, forced-titration study was conducted to evaluate the antihypertensive efficacy of candesartan vs. losartan in 654 hypertensive patients with a diastolic blood pressure between 95 and 114 mm Hg from 72 sites throughout the U.S. Eligible patients were randomized to candesartan cilexetil 16 mg once daily, or losartan 50 mg once daily. Two weeks following randomization, patients doubled the respective doses of their angiotensin receptor blockers for an additional 6 weeks. At week 8, candesartan cilexetil lowered trough systolic/diastolic blood pressure by a significantly greater amount than did losartan (13.3/10.9 mm Hg with candesartan cilexetil vs. 9.8/8.7 mm Hg with losartan; p less than 0.001). At the same period, candesartan cilexetil also lowered peak blood pressure by a significantly greater amount than did losartan (15.2 to 11.6 mm Hg with candesartan cilexetil vs. 12.6 to 10.1 mm Hg with losartan; p less than 0.05). There were statistically significantly (p less than 0.05) higher proportions of responders and controlled patients in the candesartan cilexetil group (62.4% and 56.0%, respectively) than in the losartan group (54.0% and 46.9%, respectively). Both treatment regimens were well tolerated; 1.8% in the candesartan cilexetil group and 1.6% in the losartan group withdrew because of adverse events. In conclusion, this forced-titration study confirms that candesartan cilexetil is more effective than losartan in lowering blood pressure when both are administered once daily at maximum doses. Both drugs were well tolerated. (c)2001 by Le Jacq.
Authors:
G Bakris; A Gradman; M Reif; M Wofford; M Munger; S Harris; J Vendetti; E L Michelson; R Wang;
Related Documents :
540457 - Assessment of the antihypertensive effect of atenolol with 24 h ambulatory monitoring o...
7547097 - The effect of tenidap on the anti-hypertensive efficacy of ace inhibitors in patients t...
7102527 - Once-daily pindolol in hypertension: an ambulatory assessment.
15500377 - Telmisartan/hydrochlorothiazide combination therapy in the treatment of essential hyper...
1291647 - Peptides as targets for antihypertensive drug development.
1697377 - Anti-ischemic activity of the novel benzazepine calcium antagonist sq 31,486.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of clinical hypertension (Greenwich, Conn.)     Volume:  3     ISSN:  1524-6175     ISO Abbreviation:  J Clin Hypertens (Greenwich)     Publication Date:    2001 Jan-Feb
Date Detail:
Created Date:  2001-06-25     Completed Date:  2001-08-02     Revised Date:  2013-05-28    
Medline Journal Info:
Nlm Unique ID:  100888554     Medline TA:  J Clin Hypertens (Greenwich)     Country:  United States    
Other Details:
Languages:  eng     Pagination:  16-21     Citation Subset:  IM    
Affiliation:
Department of Preventive Medicine, Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antihypertensive Agents / pharmacology*
Benzimidazoles / pharmacology*
Biphenyl Compounds / pharmacology*
Double-Blind Method
Drug Administration Schedule
Female
Humans
Hypertension / drug therapy*
Losartan / pharmacology*
Male
Middle Aged
Tetrazoles*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 0/Benzimidazoles; 0/Biphenyl Compounds; 0/Tetrazoles; 114798-26-4/Losartan; R85M2X0D68/candesartan cilexetil

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Physician Role in Lack of Awareness and Control of Hypertension.
Next Document:  Diastolic dysfunction in arterial hypertension.